Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Tratamento da Dor Cervicogênica Crônica de Cabeça e Pescoço (CGH)

30 de setembro de 2026 atualizado por: Richard Hallgren, Michigan State University

Tratamento da Dor Crônica Cervicogênica na Cabeça e Pescoço com Manipulação Osteopática e Terapia de Exercícios

The primary aim is to test the combined effectiveness of OMT and targeted head exercise (THE) to achieve a significant decrease in headache measures of frequency, intensity, and duration in a Treatment group when compared to a Control group whose members receive only standard medical care. A parallel, 2-arm, longitudinal, randomized controlled trial (RCT) will focus upon female patients (18 to 75 years of age) who have been diagnosed with chronic cervicogenic headache (CeH) based upon a differential diagnosis that includes classification according to the International Headache Society Classification IHSD 3rd Edition, reproduction of referred headache resulting from manual pressure over the upper cervical regions, and objective MRI findings. It is estimated that a sample size of 30 will provide sufficient statistical power (79%) to detect an intervention effect that corresponds to a clinically meaningful recovery (60%).

CeH is classified as a secondary headache disorder because the headache pain is a consequence of injury to, or disease of, the bony and/or soft tissues of the upper cervical spine. It has been reported that some patients diagnosed with CeH demonstrate atrophy and/or fatty infiltration (FI) of the RCPm muscles on MRI. FI and/or a reduction in the cross-sectional area (CSA) of active muscle would not be expected to be the direct cause of chronic headache, but either or both could prevent muscles from generating normal physiologic levels of force. It has been shown that there is a functional connection between the pain sensitive dura mater and RCPm muscles and it is known that mechanical stretching of the dura mater results in referred headache.

While FI and/or a reduction in the CSA of active muscle would not be expected to be the direct cause of chronic headache, it is known that muscle pathology will result in functional deficits. It is proposed that pathology in RCPm muscles will compromise the normal functional relationship between the RCPm and the dura mater and result in referred head and neck pain. It is predicted that at the end of the study, the Treatment group will show a significant decrease in headache measures that will be accompanied by a significant increase in CSA and a significant decrease in FI on MRI, and restoration of a normal head posture that will not be seen in the Control group.

The proposed study is unique in that we are proposing both a mechanism and a source for some instances of CeH. By testing the effectiveness of specific interventions to address a specific pathology within a specific headache population, and by restricting the study cohort to female subjects presenting with CeH, this study will increase the ability to detect a significant change in the outcomes by increasing the power of the statistical analysis.

Visão geral do estudo

Descrição detalhada

CeH preferentially effects female headache patients (Racicki et al., 2013). CeH is classified as a secondary headache disorder because the source of the pain is thought to be a consequence of injury to, or disease of, the bony and/or soft tissues of the upper cervical spine (Kristoffersen et al., 2017). Clinical management of CeH is challenging for the physician because a pathology that would account for the pain is usually unknown.

The primary diagnostic criteria that physicians use to diagnose CeH is based upon classification according to the International Headache Society Classification IHSD 3rd Edition (HIS, 2013). CeH is characterized by unilateral head or face pain without side shift that is of moderate to severe intensity of varying duration (Antonaci et al., 2001). CeH may occasionally be bilateral, throbbing, and accompanied by nausea, vomiting, phonophobia, photophobia, and dizziness when chronic tension-type headache and chronic migraine attacks are superimposed (Biondi, 2005). If the source of CeH originates in the upper cervical spine, osteopathic physicians can use head and neck movements and pressure applied to the suboccipital and lower cervical regions (Anarte-Lazo et al., 2021) to provoke referred headache. These diagnostic techniques, along with restricted active and passive range of motion (ROM) of the head and neck (Ogince et al., 2007), provide additional credibility that the diagnosis of CeH is valid (Avijgan et al., 2020) and helps ensure that the efficacy of our treatment protocol is not weakened by applying it to subjects with a different type of headache, such as migraine, that would not be expected to respond to a treatment protocol designed for CeH patients (Bogduk N, 2014).

The largest study of conservative therapy for cervicogenic headache (Jull et al., 2002) reported that manual therapy alone was not more effective than exercises alone. The study reported that headache frequency was reduced by 50% at a 7-week follow up, but figures for reduction in pain intensity were not reported. They reported that combining manipulation and exercise was not significantly superior to either therapy alone. Hidalgo et al., (2017) have reported that combining the 2 therapies is better than either manipulation or exercise alone. The weakness of Jull et al's. (2002) study was that their treatment protocol was applied to subjects who would not have had a common etiology for their headache pain. CeH is defined by injury to, or disease of, the bony and/or soft tissues of the upper cervical spine (Bogduk N, 2014). MRI is the gold standard for diagnostic assessment of structures of the upper cervical spine (Sun et al., 2020), but Jull et, al.'s (2002) study did not include an MRI assessment of the upper cervical spine in their inclusion/exclusion criteria. The outcome of their study reported that their treatment protocol showed a positive effect, but not one that rose to a significant level. I suggest this was due to mixing headache types (CM and CeH) that have different etiologies and expecting a single treatment protocol to address both pathologies.

Since CeH results from injury to, or disease of, the bony and/or soft tissues of the upper cervical spine, it is only reasonable to exclude those patients who do not present with pathology on MRI in the upper cervical spine (Sun et al.,2020). Our study is unique in that we will test the effectiveness of specific interventions that address a specific pathology within a specific headache population. By actively restricting the study cohort to a specific headache population, we will increase our ability to detect a significant change in the outcomes of treatment by increasing the power of the statistical analysis.

This study is unique in that it proposes to investigate a mechanism responsible for referred pain in some instances of chronic CeH. The effectiveness of specific interventions to address a specific pathology within a specific headache population will be tested. It is proposed that pathology in RCPm muscles has been undervalued, primarily because of their small size and a misunderstanding of their functional significance. By actively restricting the study cohort to a specific headache population, the power of the statistical analysis will be increased. It is hypothesized that the combined use of OMT and THE will decrease headache measures of frequency, intensity and duration, will increase the CSA and reduce the percentage of fatty infiltration (FI) of RCPm muscles on MRI, and will reduce forward head posture (FHP) in female patients diagnosed with CeH.

Tipo de estudo

Intervencional

Inscrição (Real)

1

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Michigan
      • East Lansing, Michigan, Estados Unidos, 48824
        • Michigan State University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria: Females diagnosed with chronic cervicogenic headache.

Exclusion Criteria:

  • Have you been involved in a rear-end motor vehicle accident within the past 3 years?
  • Have you had spinal surgery performed on your neck?
  • Do you have a pinched nerve in the neck that produces pain radiating down your arm.
  • Have you been diagnosed with diseases such as rheumatoid arthritis, lupus, or ankylosing spondylitis.
  • Do you have ongoing central nervous system pathology such as hemiparesis, cervical radiculopathy, spondylolisthesis grade III or IV, central nervous system causes of balance & coordination deficits, orthostatic hypotension, vestibular disorders, pregnancy, recent spinal fractures, moderate to severe traumatic brain injury.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment

All subjects in the Treatment group will receive OMT a minimum 4 times and a maximum of 8 times at the physician's (JJR) discretion (Jull et al., 2002). All subjects in the Treatment group will be taught the THE. This voluntary head retraction/protrusion exercise protocol engages the RCPm muscles in eccentric and isometric contractions that should strengthen the muscles and thereby increase CSA.

At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.

The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head.

Sem intervenção: Control

All subjects assigned to the Control group will be allowed to continue to receive conservative care. It is understood that any care that they receive will be prescribed on an individual basis. A participant could therefore receive any combination of medical, physio therapeutic and psychological care. It would also be expected that some form of pain management will be a priority for participants with moderate to severe symptoms. Subjects assigned to the Control group will not receive OMT and will not be taught the THE protocol.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cervicogenic Headache
Prazo: 18 months

Reduction of headache frequency

18 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de setembro de 2022

Conclusão Primária (Real)

7 de abril de 2025

Conclusão do estudo (Real)

1 de junho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de novembro de 2022

Primeira postagem (Real)

15 de novembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever